Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
25%, primarily to albumin.
Negligible for electrolytes and dextrose (<5%).
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Intravenous: 100%.
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INTROPIN vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.